Paperpal Prime Logo

Clinical and Applied Thrombosis/Hemostasis : Impact Factor & More

eISSN: 1938-2723pISSN: 1076-0296
JournalOpen Access

Key Metrics

CiteScore
4
H-Index
59
Impact Factor
< 5
SJR
Q2Hematology
SNIP
1.05
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Clinical and Applied Thrombosis/Hemostasis

Clinical and Applied Thrombosis/Hemostasis Journal Specifications

Overview
Publisher SAGE PUBLICATIONS INC
Language English
Frequency Continuous publication
Article Processing ChargesUSD 2500
Publication Time8
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year1995
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 8
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC BY-NC
OA statementVisit website
View less

Planning to publish in Clinical and Applied Thrombosis/Hemostasis ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Clinical and Applied Thrombosis/Hemostasis

Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
  • 11 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
Knowledge Drives Venous Thromboembolism Prevention: Structural Equation Modeling Insights Into Physicians\u2019 Knowledge, Attitudes and Practices in Chinese Public Hospitals
  • 11 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
Upregulation of Serum miRNA-3615 Serves as a Biomarker to Predict Disease Onset and Prognosis in Acute Coronary Syndrome Patients
  • 11 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
The Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries \u2013 For Whom, by Whom and Where?
  • 11 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
LncRNA HOXA11-AS Promotes Myocardial Injury in Chronic Heart Failure by Sponging miR-342-3p
  • 11 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
Derivation and Validation of a Genotype- Guided Warfarin Dosing Model in a Mixed Arab Population
  • 9 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
Rivaroxaban versus Low Molecular Weight Heparin for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
  • 11 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
Knowledge Drives Venous Thromboembolism Prevention: Structural Equation Modeling Insights Into Physicians\u2019 Knowledge, Attitudes and Practices in Chinese Public Hospitals
  • 11 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
Upregulation of Serum miRNA-3615 Serves as a Biomarker to Predict Disease Onset and Prognosis in Acute Coronary Syndrome Patients
  • 11 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
The Dilemma of Providing Advanced Hemophilia Treatments in Developing Countries \u2013 For Whom, by Whom and Where?
  • 11 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
LncRNA HOXA11-AS Promotes Myocardial Injury in Chronic Heart Failure by Sponging miR-342-3p
  • 11 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis
Derivation and Validation of a Genotype- Guided Warfarin Dosing Model in a Mixed Arab Population
  • 9 Jun 2026
  • Clinical and Applied Thrombosis/Hemostasis

FAQs on Clinical and Applied Thrombosis/Hemostasis